|
Jul 24
|
Novartis' (VTX:NOVN) Performance Is Even Better Than Its Earnings Suggest
|
|
Jul 23
|
Rheumatoid Arthritis Therapeutics Market Forecast Report 2025-2034 | Rising Preference for Combination Therapies, and Entry of Generic Drugs Supports Expansion
|
|
Jul 23
|
Epilepsy Drugs Market Growth Analysis, Forecast Trends and Outlook Report 2025-2034 | Demand for Generic Epilepsy Drugs Rises as Patent Expirations Fuel Market Growth
|
|
Jul 22
|
Analysis Group Co-Authors Examine the Advancements in and Application of Health Economics and Outcomes Research to the Evaluation of Cell and Gene Therapies for Rare Diseases
|
|
Jul 22
|
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures
|
|
Jul 22
|
Novartis AG (NVS): Jim Cramer Wonders Whether Its CEO Is Leaving [UPDATED]
|
|
Jul 22
|
AstraZeneca Plans to Invest $50B in US Manufacturing and Research by 2030
|
|
Jul 22
|
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
|
|
Jul 22
|
Novartis’ Zolgensma sales fall again as gene therapy market woes persist
|
|
Jul 2
|
Buy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July Start
|
|
Jul 2
|
What's Fueling Tempus AI's Explosive Sales Growth?
|
|
Jul 2
|
Can China sustain a surge in oncology drug innovation?
|
|
Jul 1
|
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
|
|
Jul 1
|
Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?
|
|
Jun 28
|
Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion
|
|
Jun 27
|
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
|
|
Jun 26
|
Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?
|
|
Jun 26
|
Incyte replaces CEO Hoppenot with dealmaker Meury
|
|
Jun 26
|
Kashiv BioSciences reports positive results from trial of Xolair biosimilar
|
|
Jun 26
|
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease
|